NCT05227287

ADH1 and ADH2 Disease Monitoring Study (DMS)

Autosomal Dominant Hypocalcemia Types 1 And 2 (ADH1/2) Disease Monitoring Study (DMS)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 95 (actual)
• Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company · Industry
• Sex: All
• Age: 90 Years
• Healthy volunteers: Not accepted

Summary

A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

Detailed description

The ADH1 and ADH2 DMS is designed to better understand the disease burden of ADH1 and ADH2, how participants with ADH1 or ADH2 are managed with standard of care practices in a real-world setting, and how standard of care treatment impacts ADH1 and ADH2 symptoms. The study will include adult and pediatric participants with a confirmed clinical diagnosis of ADH1 or ADH2. Each participant's data will be collected over a period of up to 5 years. In addition, retrospective (or past) data will be collected.

Conditions

• Autosomal Dominant Hypocalcemia

Timeline

• Start date: 2022-01-20
• Primary completion: 2028-11-01
• Completion: 2028-12-01
• First posted: 2022-02-07
• Last updated: 2025-04-04

Locations

27 sites across 13 countries: United States, Australia, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Portugal, United Kingdom